(CTNM) Contineum Therapeutics - Ratings and Ratios
CNS,Pain,Inflammation
CTNM EPS (Earnings per Share)
CTNM Revenue
Description: CTNM Contineum Therapeutics
Contineum Therapeutics, Inc. is a pharmaceutical company listed on NASDAQ under the ticker symbol CTNM. The companys stock is classified as a common stock, and it is based in the United States. As a player in the pharmaceuticals industry, Contineum Therapeutics is likely involved in the development, manufacturing, and distribution of therapeutic treatments.
The companys quarterly tax provision data suggests that it is operating at a loss, as indicated by the negative Return on Equity (RoE) of -29.75%. This is not uncommon for pharmaceutical companies, which often invest heavily in research and development (R&D) and may not generate profits until their products are approved and commercialized. Key drivers of the companys stock performance may include R&D milestones, regulatory approvals, and partnerships or collaborations.
To evaluate the companys potential, investors may consider key performance indicators (KPIs) such as R&D expenses as a percentage of revenue, pipeline development progress, and cash burn rate. The companys market capitalization of $174.12 million suggests that it is a relatively small-cap stock, which may be associated with higher volatility and potential for growth. The absence of a reported P/E ratio and forward P/E ratio further supports the notion that the company is not yet profitable.
From a trading perspective, the stocks price movement and volatility may be influenced by factors such as average trading volume, short interest, and institutional ownership. With an average volume of 183,100 shares, the stock appears to have a relatively moderate level of liquidity. Investors may also consider the stocks beta, although it is not reported in this case. A more detailed analysis of the companys financials, management team, and industry trends would be necessary to form a comprehensive view of its investment potential.
CTNM Stock Overview
| Market Cap in USD | 313m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2024-04-05 |
CTNM Stock Ratings
| Growth Rating | -72.1% |
| Fundamental | 22.3% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -45.4% |
| Analyst Rating | 4.60 of 5 |
CTNM Dividends
Currently no dividends paidCTNM Growth Ratios
| Growth Correlation 3m | 91.6% |
| Growth Correlation 12m | -76.3% |
| Growth Correlation 5y | -79.6% |
| CAGR 5y | -16.51% |
| CAGR/Max DD 3y | -0.20 |
| CAGR/Mean DD 3y | -0.47 |
| Sharpe Ratio 12m | -1.44 |
| Alpha | -46.69 |
| Beta | 0.647 |
| Volatility | 89.93% |
| Current Volume | 198.6k |
| Average Volume 20d | 205.3k |
| Stop Loss | 11.4 (-7.8%) |
| Signal | 0.67 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-56.9m TTM) > 0 and > 6% of Revenue (6% = 14.5k TTM) |
| FCFTA -0.18 (>2.0%) and ΔFCFTA -26.79pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 70.1k% (prev 433.2%; Δ 69.7kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.25 (>3.0%) and CFO -46.4m > Net Income -56.9m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 24.51 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (25.9m) change vs 12m ago 0.67% (target <= -2.0% for YES) |
| Gross Margin 17.36% (prev 99.68%; Δ -82.33pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.12% (prev 22.59%; Δ -22.47pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -12.17
| (A) 0.93 = (Total Current Assets 176.8m - Total Current Liabilities 7.21m) / Total Assets 182.9m |
| (B) -0.82 = Retained Earnings (Balance) -149.4m / Total Assets 182.9m |
| (C) -0.29 = EBIT TTM -59.0m / Avg Total Assets 202.1m |
| (D) -12.98 = Book Value of Equity -149.3m / Total Liabilities 11.5m |
| Total Rating: -12.17 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 22.28
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield -23.25% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.03 = 2.50 |
| 5. Debt/Ebitda -0.10 = -2.50 |
| 6. ROIC - WACC -39.11% = -12.50 |
| 7. RoE -29.75% = -2.50 |
| 8. Rev. Trend -28.55% = -1.43 |
| 9. Rev. CAGR 0.0% = 0.0 |
| 10. EPS Trend -51.63% = -1.29 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of CTNM shares?
Over the past week, the price has changed by +1.85%, over one month by +70.18%, over three months by +188.00% and over the past year by -35.42%.
Is Contineum Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CTNM is around 11.85 USD . This means that CTNM is currently overvalued and has a potential downside of -4.13%.
Is CTNM a buy, sell or hold?
- Strong Buy: 3
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CTNM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 22.9 | 85.1% |
| Analysts Target Price | 22.9 | 85.1% |
| ValueRay Target Price | 13.2 | 6.7% |
Last update: 2025-09-04 04:35
CTNM Fundamental Data Overview
CCE Cash And Equivalents = 175.5m USD (Cash And Short Term Investments, last quarter)
P/S = 11.147
P/B = 1.8276
Beta = None
Revenue TTM = 242.0k USD
EBIT TTM = -59.0m USD
EBITDA TTM = -58.7m USD
Long Term Debt = 4.28m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 1.47m USD (from shortTermDebt, last quarter)
Debt = 5.75m USD (Calculated: Short Term 1.47m + Long Term 4.28m)
Net Debt = -15.0m USD (from netDebt column, last quarter)
Enterprise Value = 143.5m USD (313.2m + Debt 5.75m - CCE 175.5m)
Interest Coverage Ratio = unknown (Ebit TTM -59.0m / Interest Expense TTM 0.0)
FCF Yield = -23.25% (FCF TTM -33.4m / Enterprise Value 143.5m)
FCF Margin = -13.8k% (FCF TTM -33.4m / Revenue TTM 242.0k)
Net Margin = -23.5k% (Net Income TTM -56.9m / Revenue TTM 242.0k)
Gross Margin = 17.36% ((Revenue TTM 242.0k - Cost of Revenue TTM 200.0k) / Revenue TTM)
Tobins Q-Ratio = -0.96 (set to none) (Enterprise Value 143.5m / Book Value Of Equity -149.3m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 5.75m)
Taxrate = 21.0% (US default)
NOPAT = -59.0m (EBIT -59.0m, no tax applied on loss)
Current Ratio = 24.51 (Total Current Assets 176.8m / Total Current Liabilities 7.21m)
Debt / Equity = 0.03 (Debt 5.75m / last Quarter total Stockholder Equity 171.4m)
Debt / EBITDA = -0.10 (Net Debt -15.0m / EBITDA -58.7m)
Debt / FCF = -0.17 (Debt 5.75m / FCF TTM -33.4m)
Total Stockholder Equity = 191.1m (last 4 quarters mean)
RoA = -31.09% (Net Income -56.9m, Total Assets 182.9m )
RoE = -29.75% (Net Income TTM -56.9m / Total Stockholder Equity 191.1m)
RoCE = -30.19% (Ebit -59.0m / (Equity 191.1m + L.T.Debt 4.28m))
RoIC = -30.86% (NOPAT -59.0m / Invested Capital 191.1m)
WACC = 8.25% (E(313.2m)/V(319.0m) * Re(8.40%)) + (D(5.75m)/V(319.0m) * Rd(0.0%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 73.96 | Cagr: 0.30%
Discount Rate = 8.40% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -33.4m)
Revenue Correlation: -28.55 | Revenue CAGR: 0.0%
Rev Growth-of-Growth: 1600
EPS Correlation: -51.63 | EPS CAGR: 0.0%
EPS Growth-of-Growth: -4.18
Additional Sources for CTNM Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle